Business Context and Reporting Period
This Form 8-K filing by Oaktree Acquisition Corp. III Life Sciences (the "Company") is dated December 11, 2024. The Company is a Cayman Islands entity incorporated as a special purpose acquisition company (SPAC) focused on the life sciences sector. The report details a corporate action regarding the trading structure of its securities.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event regarding securities trading rather than financial performance.
Material Changes
The primary material change reported is the commencement of separate trading for the components of the Company's Units. Effective December 16, 2024, holders may elect to separate their Units into Class A ordinary shares and redeemable warrants. Previously, these securities traded together as Units under the symbol "OACCU."
Guidance, Outlook, and Management Commentary
- Separate Trading: Commencing December 16, 2024, Class A ordinary shares will trade under the symbol "OACC" and warrants under "OACCW" on the Nasdaq Global Market.
- Unit Composition: Each Unit consists of one Class A ordinary share and one-fifth of one redeemable warrant. The warrant exercise price is $11.50 per share.
- Procedural Requirements: Holders must instruct their brokers to contact the transfer agent, Continental Stock Transfer & Trust Company, to effectuate the separation. No fractional warrants will be issued; only whole warrants will trade.
- Continued Trading: Units that are not separated will continue to trade under the symbol "OACCU."
Investor Verification Checklist
- Verify the effective date of separate trading (December 16, 2024) with your brokerage firm.
- Confirm the specific symbols for the separated securities: "OACC" for shares and "OACCW" for warrants.
- Ensure your broker has initiated contact with Continental Stock Transfer & Trust Company if you intend to separate your Units.
- Review the attached press release (Exhibit 99.1) for any additional terms regarding the separation process.